Calendar
Filter Events
March 2024
Machine Learning for Kidney Disease
A Science & Innovation Webinar, sponsored by Boehringer Ingelheim.
Validated tools are needed to estimate the risk of the more than 35 million adults living with chronic kidney disease (CKD). Boehringer Ingelheim and Carelon Research have conducted the first large-scale US validation of a new AI-driven tool for chronic kidney disease. This program will discuss the Klinrisk AI model's capability to predict disease progression in individuals at all stages of CKD.
MEMBERS
NON-MEMBERS
March 2024
Navigating the Landscape of Food Allergies: Payer Insights and Perspectives from AMCP Market Insights
As new therapeutic options emerge for managing food allergies, managed care organizations face the crucial task of evaluating their clinical efficacy and safety profiles to formulate coverage policies. Considering the potential for new therapeutics to reduce emergency room visits and enhance patents' quality of life, it is essential to assess the cost implications comprehensively.
Join us for this webinar as we delve into these critical considerations and explore strategies to accommodate innovative treatments in managed care.
March 2024
A New First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
A Pre-Approval Information Exchange (PIE) Webinar, sponsored by Elevar Therapeutics.
You are invited to attend a virtual PIE Webinar about a new investigational treatment for unresectable or metastatic hepatocellular carcinoma (uHCC): Rivoceranib + Camrelizumab.
This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions®.
This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.
MEMBERS
NON-MEMBERS
April 2024
An Investigational Targeted Treatment for mIDH Glioma
A Pre-Approval Information Exchange (PIE) Webinar sponsored by Servier.
Servier, a global pharmaceutical group, is excited to provide an overview of vorasidenib, an investigational treatment for patients with mIDH glioma. As the potential first-in-class targeted therapy for mIDH glioma, vorasidenib was granted fast track designation by the FDA, with an anticipated PDUFA date in Q3 2024. This webinar will provide an overview of mIDH glioma and highlight the clinical information of vorasidenib.
This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions®.
This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.
MEMBERS
NON-MEMBERS
April 2024
The Evolution of Care for IBD Patients
Inflammatory Bowel Disease (IBD) is a chronic, unpredictable, inflammatory disorder of the digestive tract with major clinical and economic burden. The American Gastroenterological Association Guidelines and the STRIDE-II Recommendations include long-term goals for the management of IBD, with a focus on long-term patient outcomes. The objective of this webinar is to review IBD, treatment guidelines and professional recommendations, clinical decision making and the associated economic burden.
MEMBERS
NON-MEMBERS
April 2024
AMCP 2024
- Registration opens Dec. 12 for AMCP Members, Dec. 14 for all
August 2024
October 2024
AMCP Nexus 2024
- Call for Session Proposals - submission portal opens Mar. 18, 2024
- Call for Poster Abstracts - submission portal opens Mar. 18, 2024